Loading...
Header Logo
Keywords
Last Name
Institution

GEORGE R BLUMENSCHEIN

TitleProfessor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 May 08; JCO1900201. PMID: 31067138.
      View in: PubMed
    2. Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 Mar 01; 30(3):471-477. PMID: 30596812.
      View in: PubMed
    3. Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Lee JJ, Heymach JV, Zhang J. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 Jun; 14(6):1021-1031. PMID: 30780001.
      View in: PubMed
    4. Wheatley-Price P, Gadgeel S, Takahashi T, Li X, Dar M, Blumenschein GR. Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2019 May; 20(3):e362-e368. PMID: 30685114.
      View in: PubMed
    5. Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist. 2018 Sep; 23(9):1079-1082. PMID: 29866947.
      View in: PubMed
    6. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018 Jun; 81:45-51. PMID: 29884413.
      View in: PubMed
    7. Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res. 2018 Jun 15; 24(12):2771-2779. PMID: 29563138.
      View in: PubMed
    8. Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). J Thorac Oncol. 2018 05; 13(5):682-688. PMID: 29518553.
      View in: PubMed
    9. Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 Jun 20; 36(18):1813-1822. PMID: 29293386.
      View in: PubMed
    10. Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646. PMID: 28899363.
      View in: PubMed
    11. Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1104-1115. PMID: 28651929.
      View in: PubMed
    12. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017 06 22; 376(25):2415-2426. PMID: 28636851.
      View in: PubMed
    13. Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017 Sep 01; 35(25):2885-2892. PMID: 28493811.
      View in: PubMed
    14. Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM, Blumenschein G. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566. PMID: 27876675.
      View in: PubMed
    15. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682. PMID: 27789196.
      View in: PubMed
    16. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 11 10; 375(19):1856-1867. PMID: 27718784.
      View in: PubMed
    17. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38. PMID: 26933802.
      View in: PubMed
    18. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22; 373(17):1627-39. PMID: 26412456.
      View in: PubMed
    19. Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24. PMID: 25968826.
      View in: PubMed
    20. Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2462-70. PMID: 26034219.
      View in: PubMed
    21. Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1476-80. PMID: 26025965.
      View in: PubMed
    22. Gomez DR, Liao KP, Swisher SG, Blumenschein GR, Erasmus JJ, Buchholz TA, Giordano SH, Smith BD. Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. Radiother Oncol. 2015 May; 115(2):257-63. PMID: 26013292.
      View in: PubMed
    23. Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015 May; 37(5):644-9. PMID: 24585506.
      View in: PubMed
    24. Blumenschein GR, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Jänne PA. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Ann Oncol. 2015 May; 26(5):894-901. PMID: 25722381.
      View in: PubMed
    25. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W, Choy H. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb; 16(2):187-99. PMID: 25601342.
      View in: PubMed
    26. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46. PMID: 25313136.
      View in: PubMed
    27. Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist. 2014 Oct; 19(10):1040-1. PMID: 25170013.
      View in: PubMed
    28. Komaki R, Paulus R, Blumenschein GR, Curran WJ, Robert F, Thariat J, Werner-Wasik M, Choy H, Hirsch FR, Ang KK. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol. 2014 Jul; 112(1):30-6. PMID: 25042878.
      View in: PubMed
    29. Ganesan P, Ali SM, Wang K, Blumenschein GR, Esmaeli B, Wolff RA, Miller VA, Stephens PJ, Ross JS, Palmer GA, Janku F. Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. J Clin Oncol. 2016 Feb 10; 34(5):e34-7. PMID: 24934779.
      View in: PubMed
    30. Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75. PMID: 24166906.
      View in: PubMed
    31. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013 Nov 10; 31(32):4105-14. PMID: 24101053.
      View in: PubMed
    32. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer. 2013 Oct; 13(5):378-84. PMID: 23810431.
      View in: PubMed
    33. Groen HJ, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, Butts CA, Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, Tye L, Chao RC, Blumenschein GR. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol. 2013 09; 24(9):2382-9. PMID: 23788751.
      View in: PubMed
    34. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61. PMID: 23584298.
      View in: PubMed
    35. Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42. PMID: 23442309.
      View in: PubMed
    36. Shepherd FA, Douillard JY, Blumenschein GR. [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome]. Zhongguo Fei Ai Za Zhi. 2013 Apr; 16(4):C9-20. PMID: 23601304.
      View in: PubMed
    37. Gonzalez-Angulo AM, Blumenschein GR. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev. 2013 Jun; 39(4):313-20. PMID: 23218708.
      View in: PubMed
    38. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52. PMID: 23059780.
      View in: PubMed
    39. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90. PMID: 23091115.
      View in: PubMed
    40. Blumenschein GR, Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, Tye L, Chao RC, Juhasz E. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. J Thorac Oncol. 2012 Sep; 7(9):1406-16. PMID: 22743295.
      View in: PubMed
    41. Raghav KP, Gonzalez-Angulo AM, Blumenschein GR. Role of HGF/MET axis in resistance of lung cancer to contemporary management. Transl Lung Cancer Res. 2012 Sep; 1(3):179-93. PMID: 25806180.
      View in: PubMed
    42. Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN, Blumenschein G. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 2013 Apr; 31(2):417-24. PMID: 22918720.
      View in: PubMed
    43. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013 Jan; 24(1):220-5. PMID: 22898037.
      View in: PubMed
    44. Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol. 2012 Sep 10; 30(26):3287-96. PMID: 22869872.
      View in: PubMed
    45. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013 Jan 01; 119(1):7-15. PMID: 22736407.
      View in: PubMed
    46. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77. PMID: 22374333.
      View in: PubMed
    47. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39. PMID: 22247021.
      View in: PubMed
    48. Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol. 2011; 1:52. PMID: 22649768.
      View in: PubMed
    49. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11. PMID: 21892101.
      View in: PubMed
    50. Blumenschein G. Insulin-like growth factor receptor. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1799-800. PMID: 22005535.
      View in: PubMed
    51. Kies MS, Boatright DH, Li G, Blumenschein G, El-Naggar AK, Brandon Gunn G, Lewin JS, Steinhaus GD, Sturgis EM. Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck. 2012 Sep; 34(9):1255-62. PMID: 22009800.
      View in: PubMed
    52. Blumenschein GR. Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). Invest New Drugs. 2012 Aug; 30(4):1802-11. PMID: 21987350.
      View in: PubMed
    53. Shepherd FA, Douillard JY, Blumenschein GR. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol. 2011 Oct; 6(10):1763-73. PMID: 21876456.
      View in: PubMed
    54. Belani CP, Goss G, Blumenschein G. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2012 May; 38(3):173-84. PMID: 21715100.
      View in: PubMed
    55. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53. PMID: 22586319.
      View in: PubMed
    56. Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol. 2011 Jun 10; 29(17):2312-8. PMID: 21555682.
      View in: PubMed
    57. Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs. 2011 Jun; 20(6):859-69. PMID: 21534718.
      View in: PubMed
    58. Adjei AA, Blumenschein GR, Mandrekar S, Hillman S, Gatzemeier U, Heigener D. Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clin Lung Cancer. 2011 Jul; 12(4):212-7. PMID: 21726819.
      View in: PubMed
    59. Blumenschein GR, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011 Sep; 22(9):2057-67. PMID: 21321086.
      View in: PubMed
    60. Blumenschein GR, Reck M, Fossella F, Stewart DJ, Lathia C, Peña C. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomark. 2011-2012; 10(6):287-98. PMID: 22820084.
      View in: PubMed
    61. Heath EI, Blumenschein GR, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol. 2011 Sep; 68(3):703-12. PMID: 21140147.
      View in: PubMed
    62. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15. PMID: 20855820.
      View in: PubMed
    63. William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15. PMID: 20225329.
      View in: PubMed
    64. Ross HJ, Blumenschein GR, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res. 2010 Mar 15; 16(6):1938-49. PMID: 20215545.
      View in: PubMed
    65. Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs. 2011 Jun; 29(3):499-505. PMID: 20094773.
      View in: PubMed
    66. Blumenschein GR, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res. 2010 Jan 01; 16(1):279-90. PMID: 20028752.
      View in: PubMed
    67. Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 2009 Sep 10; 27(26):4274-80. PMID: 19652055.
      View in: PubMed
    68. Phan R, Phan L, Ginsberg LE, Blumenschein G, Williams MD, Esmaeli B. Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread. Arch Ophthalmol. 2009 Aug; 127(8):1074-5. PMID: 19667357.
      View in: PubMed
    69. Liao ZX, Komaki RR, Thames HD, Liu HH, Tucker SL, Mohan R, Martel MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):775-81. PMID: 19515503.
      View in: PubMed
    70. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009 May 20; 27(15):2516-22. PMID: 19380445.
      View in: PubMed
    71. Blumenschein G. Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S124-7. PMID: 18520294.
      View in: PubMed
    72. Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S107-12. PMID: 18520291.
      View in: PubMed
    73. Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol. 2008 Apr 10; 26(11):1879-85. PMID: 18398153.
      View in: PubMed
    74. Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR, Onn A. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol. 2008 Apr; 3(4):351-7. PMID: 18379352.
      View in: PubMed
    75. Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol. 2008 Mar; 47(3):276-9. PMID: 18289332.
      View in: PubMed
    76. Williams MD, Roberts D, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007 Nov; 31(11):1645-52. PMID: 18059220.
      View in: PubMed
    77. Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008 Feb; 26(1):81-7. PMID: 17960324.
      View in: PubMed
    78. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):779-85. PMID: 17418967.
      View in: PubMed
    79. Blumenschein G, Heymach JV. Angiogenesis inhibitors for lung cancer: clinical developments and future directions. J Thorac Oncol. 2006 Sep; 1(7):744-8. PMID: 17409952.
      View in: PubMed
    80. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4441s-4445s. PMID: 16857825.
      View in: PubMed
    81. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31. PMID: 16640804.
      View in: PubMed
    82. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR, Hong WK, Wu X. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006 Jan 15; 106(2):441-7. PMID: 16342067.
      View in: PubMed
    83. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005 Dec 01; 104(11):2449-56. PMID: 16258975.
      View in: PubMed
    84. Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005 Dec 20; 23(36):9089-96. PMID: 16301597.
      View in: PubMed
    85. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005 Aug 15; 104(4):682-91. PMID: 15986399.
      View in: PubMed
    86. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55. PMID: 15753462.
      View in: PubMed
    87. Clinical targeting of VEGF and EGFR effective in non-small cell lung cancer. Cancer Biol Ther. 2004 Jul; 3(7):588-9. PMID: 15751163.
      View in: PubMed
    88. Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol. 2004 Oct; 54(4):308-14. PMID: 15184994.
      View in: PubMed
    89. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77. PMID: 15050312.
      View in: PubMed
    90. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM, Clayman G, Morrison WH, Liu DD, Blumenschein G, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer. 2003 Nov 15; 98(10):2214-23. PMID: 14601092.
      View in: PubMed
    91. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21. PMID: 12886869.
      View in: PubMed
    92. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5. PMID: 14596703.
      View in: PubMed
    93. Blumenschein GR, Herbst RS. Integration of targeted therapies in gemcitabine chemotherapy regimens. Clin Lung Cancer. 2003 Jan; 4(4):217-23. PMID: 14624709.
      View in: PubMed
    94. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol. 2002 Nov 15; 20(22):4440-7. PMID: 12431966.
      View in: PubMed
    95. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53. PMID: 12124835.
      View in: PubMed
    96. Esmaeli B, Naderi A, Hidaji L, Blumenschein G, Prieto VG. Merkel cell carcinoma of the eyelid with a positive sentinel node. Arch Ophthalmol. 2002 May; 120(5):646-8. PMID: 12003618.
      View in: PubMed
    97. Blumenschein GR, DiStefano A, Caderao J, Fristenberg B, Adams J, Schweichler LH, Drinkard L. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. Clin Cancer Res. 1997 Dec; 3(12 Pt 2):2633-7. PMID: 10068266.
      View in: PubMed
    98. Dicke KA, Hood DL, Arneson M, Fulbright L, DiStefano A, Firstenberg B, Adams J, Blumenschein GR. Effects of short-term in vivo administration of G-CSF on bone marrow prior to harvesting. Exp Hematol. 1997 Jan; 25(1):34-8. PMID: 8989904.
      View in: PubMed
    99. Dicke KA, Hood DL, Hanks S, Vaughan M, Fulbright L, Dicke JA, Arneson M, Blumenschein G. A marrow harvest procedure under local anesthesia. Exp Hematol. 1995 Oct; 23(11):1229-32. PMID: 7556535.
      View in: PubMed
    100. Oldham RK, Blumenschein G, Schwartzberg L, Birch R, Arnold J. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother. 1992 Mar; 4(1):4-9. PMID: 1627272.
      View in: PubMed
    101. Dillman RO, Oldham RK, Tauer KW, Orr DW, Barth NM, Blumenschein G, Arnold J, Birch R, West WH. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol. 1991 Jul; 9(7):1233-40. PMID: 2045864.
      View in: PubMed
    102. Fraschini G, Yap HY, Mann G, Buzdar AU, Blumenschein GR, Hortobagyi GN. Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. Cancer. 1987 Oct 15; 60(8):1724-8. PMID: 3652000.
      View in: PubMed
    103. Holmes FA, Yap HY, Esparza L, Buzdar AU, Blumenschein GR, Hug V, Hortobagyi GN. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. Cancer. 1987 Jun 15; 59(12):1992-9. PMID: 3567861.
      View in: PubMed
    104. Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, Smith TL, Blumenschein GR, Yap HY, Rodriguez V. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987 Mar; 5(3):354-64. PMID: 3819804.
      View in: PubMed
    105. Hortobagyi GN, Buzdar AU, Bodey GP, Kau S, Rodriguez V, Legha SS, Yap HY, Blumenschein GR. High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol. 1987 Feb; 5(2):178-84. PMID: 3543241.
      View in: PubMed
    106. Herring MK, Buzdar AU, Smith TL, Hortobagyi GN, Blumenschein GR. Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol. 1986 Jun; 9(3):269-75. PMID: 3755282.
      View in: PubMed
    107. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986 May; 46(5):2578-81. PMID: 3697997.
      View in: PubMed
    108. Lee RW, Buzdar AU, Blumenschein GR, Hortobagyi GN. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer. 1986 Jan 01; 57(1):40-3. PMID: 3940620.
      View in: PubMed
    109. Holmes FA, Esparza L, Yap HY, Buzdar AU, Blumenschein GR, Hortobagyi GN. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1986; 18(2):157-61. PMID: 3791560.
      View in: PubMed
    110. Casimir MT, Buzdar AU, Blumenschein GR, Hortobagyi GN, Bodey GP. Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. Oncology. 1986; 43(4):205-7. PMID: 3755230.
      View in: PubMed
    111. Hortobagyi GN, Buzdar AU, Blumenschein GR, Yap HY, Hersh EM. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. Dev Biol Stand. 1986; 58 ( Pt A):357-63. PMID: 3596041.
      View in: PubMed
    112. Pasterz RB, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1985 Nov 15; 56(10):2381-4. PMID: 4042070.
      View in: PubMed
    113. Fraschini G, Yap HY, Hortobagyi GN, Buzdar A, Blumenschein G. Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer. 1985 Jul 15; 56(2):225-9. PMID: 4005794.
      View in: PubMed
    114. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985 Jun 15; 55(12):2761-5. PMID: 3922612.
      View in: PubMed
    115. Hug V, Rashid R, Blumenschein G, Spitzer G. Clonogenic in vitro growth and histologic grading of primary human breast tumors. Int J Cell Cloning. 1985 May; 3(3):143-8. PMID: 4008996.
      View in: PubMed
    116. Hug V, Burgess A, Blumenschein G, Hortobagyi G, Cohen AG. Effect of cyclophosphamide on the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura. Cancer Treat Rep. 1985 May; 69(5):565-6. PMID: 4039981.
      View in: PubMed
    117. Fastenberg NA, Martin RG, Buzdar AU, Hortobagyi GN, Montague ED, Blumenschein GR, Jessup JM. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol. 1985 Apr; 8(2):134-41. PMID: 3841746.
      View in: PubMed
    118. Singletary SE, Umbach GE, Spitzer G, Drewinko B, Tomasovic B, Ajani J, Hug V, Blumenschein G. The human tumor stem cell assay revisited. Int J Cell Cloning. 1985 Mar; 3(2):116-28. PMID: 3998518.
      View in: PubMed
    119. Ross MB, Buzdar AU, Smith TL, Eckles N, Hortobagyi GN, Blumenschein GR, Freireich EJ, Gehan EA. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer. 1985 Jan 15; 55(2):341-6. PMID: 3965092.
      View in: PubMed
    120. Yau JC, Yap YY, Buzdar AU, Hortobagyi GN, Bodey GP, Blumenschein GR. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. Cancer. 1985 Jan 15; 55(2):337-40. PMID: 3880657.
      View in: PubMed
    121. Feldman LD, Buzdar AU, Blumenschein GR. High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer. Oncology. 1985; 42(5):273-4. PMID: 4034143.
      View in: PubMed
    122. Hortobagyi GN, Buzdar AU, Frye D, Yap HY, Hug V, Pinnamaneni K, Fraschini G, Halvorson HC, Blumenschein GR. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1985; 5(3):321-6. PMID: 3161565.
      View in: PubMed
    123. Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR, Montague ED. Induction chemotherapy of breast cancer. Prog Clin Biol Res. 1985; 201:105-16. PMID: 4095105.
      View in: PubMed
    124. Hug V, Drewinko B, Hortobagyi GN, Blumenschein G. Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors. Breast Cancer Res Treat. 1985; 6(3):237-40. PMID: 4092099.
      View in: PubMed
    125. Buzdar AU, Blumenschein GR. Breast cancer. Cancer Treat Rev. 1984 Dec; 11(4):315-9. PMID: 6534512.
      View in: PubMed
    126. Kantarjian HM, Hortobagyi GN, Smith TL, Blumenschein GR, Montague E, Buzdar AU, Martin RG. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984 Nov; 20(11):1353-61. PMID: 6548710.
      View in: PubMed
    127. Holmes FA, Yap HY, Esparza L, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol. 1984 Sep; 11(3 Suppl 1):28-31. PMID: 6385262.
      View in: PubMed
    128. Pinnamaneni K, Yap HY, Legha SS, Blumenschein GR, Bodey GP. Phase II study of spirogermanium in the treatment of metastatic breast cancer. Cancer Treat Rep. 1984 Sep; 68(9):1197-8. PMID: 6478457.
      View in: PubMed
    129. Tannir N, Yap HY, Hortobagyi GH, Hug V, Buzdar AU, Blumenschein GR. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep. 1984 Jul-Aug; 68(7-8):1039-41. PMID: 6547638.
      View in: PubMed
    130. Aboud A, Buzdar AU, Yap HY, Hortobagyi GN, Blumenschein GR. Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. J Surg Oncol. 1984 Jul; 26(3):205-7. PMID: 6610802.
      View in: PubMed
    131. Finnerty NA, Buzdar AU, Blumenschein GR. Radiation-induced breast cancer. Arch Intern Med. 1984 Jun; 144(6):1217-9. PMID: 6732380.
      View in: PubMed
    132. Pinnamaneni K, Yap HY, Buzdar AU, Distefano A, Blumenschein GR. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. Cancer. 1984 May 01; 53(9):1841-4. PMID: 6546706.
      View in: PubMed
    133. Tannir N, Spitzer G, Dicke K, Schell F, DiStefano A, Blumenschein G. Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer. Cancer Treat Rep. 1984 May; 68(5):805-6. PMID: 6426793.
      View in: PubMed
    134. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer. 1984 May 01; 53(9):1836-40. PMID: 6231092.
      View in: PubMed
    135. Chawla SP, Buzdar AU, Hortobagyi GN, Blumenschein GR. Tumor-associated fever in breast cancer. Cancer. 1984 Apr 01; 53(7):1596-9. PMID: 6697296.
      View in: PubMed
    136. Hug V, Thames H, Blumenschein GR, Spitzer G, Drewinko B. Normalization of in vitro sensitivity testing of human tumor clonogenic cells. Cancer Res. 1984 Mar; 44(3):923-8. PMID: 6692414.
      View in: PubMed
    137. Buzdar AU, Blumenschein GR, Smith TL, Powell KC, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Ames FC, Martin RG, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer. 1984 Feb 01; 53(3):384-9. PMID: 6362814.
      View in: PubMed
    138. Buzdar AU, Blumenschein GR, Montague ED, Hortobagyi GN, Yap HY, Pinnamaneni K, Marcus CE, Smith TL. Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol. 1984 Feb; 7(1):45-50. PMID: 6364779.
      View in: PubMed
    139. Buzdar AU, Fraschini G, Blumenschein GR. Hematologic adverse effects of aminoglutethimide. Ann Intern Med. 1984 Jan; 100(1):159. PMID: 6691645.
      View in: PubMed
    140. Buzdar AU, Smith TL, Marcus CE, Hortobagyi GN, Blumenschein GR. Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer. Recent Results Cancer Res. 1984; 96:141-7. PMID: 6396767.
      View in: PubMed
    141. Blumenschein GR, Buzdar AU, Hortobagyi GN. FAC + BCG as adjuvant therapy in breast cancer: an 8-year update. Recent Results Cancer Res. 1984; 96:129-32. PMID: 6528087.
      View in: PubMed
    142. Hug V, Thames H, Johnston D, Blumenschein G, Drewinko B, Spitzer G. The true predictive value of the human tumor stem cell assay: does a workable assay select for treatment responders? J Clin Oncol. 1984 Jan; 2(1):42-5. PMID: 6699657.
      View in: PubMed
    143. Aboud A, Yap HY, Esparza L, Blumenschein GR, Hortobagyi G, Issell B, Bodey GP. Carminomycin. A new anthracycline analog in the treatment of advanced breast cancer. Cancer. 1984 Jan 01; 53(1):9-12. PMID: 6546298.
      View in: PubMed
    144. Yap HY, Esparza L, Blumenschein GR, Hortobagyi GN, Bodey GP. Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer. Cancer Treat Rev. 1983 Dec; 10 Suppl B:53-5. PMID: 6661735.
      View in: PubMed
    145. Blumenschein GR. The role of progestins in the treatment of breast cancer. Semin Oncol. 1983 Dec; 10(4 Suppl 4):7-10. PMID: 6230722.
      View in: PubMed
    146. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, Buzdar AU, Blumenschein GR. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983 Dec; 1(12):776-86. PMID: 6668494.
      View in: PubMed
    147. Harkins LA, Yap HY, Buzdar AU, Blumenschein GR. Benign versus malignant hepatic lesions. A diagnostic dilemma with breast cancer patients. Cancer. 1983 Oct 01; 52(7):1308-11. PMID: 6883292.
      View in: PubMed
    148. Hall SM, Buzdar AU, Blumenschein GR. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement. Cancer. 1983 Jul 01; 52(1):180-4. PMID: 6850542.
      View in: PubMed
    149. Tannir N, Spitzer G, Schell F, Legha S, Zander A, Blumenschein G. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. Cancer Treat Rep. 1983 Jun; 67(6):599-600. PMID: 6344995.
      View in: PubMed
    150. Hortobagyi GN, Spanos W, Montague ED, Buzdar AU, Yap HY, Blumenschein GR. Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys. 1983 May; 9(5):643-50. PMID: 6343312.
      View in: PubMed
    151. DeMartini AL, Buzdar AU, Blumenschein GR. Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer. J Surg Oncol. 1983 May; 23(1):32-4. PMID: 6687746.
      View in: PubMed
    152. Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983 Apr 08; 249(14):1881-6. PMID: 6834584.
      View in: PubMed
    153. Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, Schell F. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983 Mar 01; 51(5):763-8. PMID: 6687377.
      View in: PubMed
    154. Hortobagyi GN, Yap HY, Blumenschein GR, Buzdar AU, Barnes BC, Legha SS, Wiseman CL. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. Cancer. 1983 Mar 01; 51(5):769-72. PMID: 6600415.
      View in: PubMed
    155. Yap HY, Yap BS, Blumenschein GR, Barnes BC, Schell FC, Bodey GP. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Cancer Res. 1983 Mar; 43(3):1402-4. PMID: 6825109.
      View in: PubMed
    156. Yap HY, Bedikian AY, Schell FC, Blumenschein GR, Bodey GP. Phase II clinical evaluation of AZQ in metastatic breast cancer. Am J Clin Oncol. 1983 Feb; 6(1):31-3. PMID: 6837505.
      View in: PubMed
    157. Yap HY, Valdivieso M, Blumenschein G, Hortobagyi G, Bedikian A. A phase I-II study of continuous 5-day infusion mitomycin-C. Am J Clin Oncol. 1983 Feb; 6(1):109-12. PMID: 6404154.
      View in: PubMed
    158. Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G. Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983 Feb; 143(2):237-40. PMID: 6824391.
      View in: PubMed
    159. Hug V, Spitzer G, Drewinko B, Blumenschein GR. Effect of diethylaminoethyl-dextran on colony formation of human tumor cells in semisolid suspension cultures. Cancer Res. 1983 Jan; 43(1):210-3. PMID: 6182989.
      View in: PubMed
    160. Stein W, Hortobagyi GN, Blumenschein GR. Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. J Surg Oncol. 1983 Jan; 22(1):45-6. PMID: 6823117.
      View in: PubMed
    161. Buzdar AU, Powell KC, Legha SS, Blumenschein GR. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. Cancer. 1982 Nov 01; 50(9):1708-12. PMID: 6180820.
      View in: PubMed
    162. Yap HY, Blumenschein GR, Hortobagyi GN, Buzdar AU, Schell FC, Bodey GP. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. Am J Clin Oncol. 1982 Oct; 5(5):511-4. PMID: 7180829.
      View in: PubMed
    163. Harvey HA, Lipton A, Lawrence BV, White DS, Wells SA, Blumenschein G, Lee D. Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol. 1982 Sep; 21(1):42-4. PMID: 7109635.
      View in: PubMed
    164. Schell FC, Yap HY, Blumenschein G, Valdivieso M, Bodey G. Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep. 1982 Aug; 66(8):1641-3. PMID: 7105054.
      View in: PubMed
    165. Wiseman CL, Yap HY, Bedikian AY, Bodey GP, Blumenschein GR. Phase II trial of bruceantin in metastatic breast carcinoma. Am J Clin Oncol. 1982 Aug; 5(4):389-91. PMID: 7113961.
      View in: PubMed
    166. Buzdar AU, Powell KC, Blumenschein GR. Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience. Cancer Res. 1982 Aug; 42(8 Suppl):3448s-3450s. PMID: 7083209.
      View in: PubMed
    167. Buzdar AU, Legha SS, Hortobagyi GN, Powell KC, Blumenschein GR, Bodey GP. AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study. Am J Clin Oncol. 1982 Aug; 5(4):383-7. PMID: 6896794.
      View in: PubMed
    168. Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR. Treatment for meningeal carcinomatosis in breast cancer. Cancer. 1982 Jul 15; 50(2):219-22. PMID: 6177395.
      View in: PubMed
    169. Yap BS, Yap HY, Blumenschein GR, Bedikian AY, Pocelinko R, Bodey GP. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene). Cancer Treat Rep. 1982 Jul; 66(7):1517-20. PMID: 7093967.
      View in: PubMed
    170. Raber MN, Barlogie B, Latreille J, Bedrossian C, Fritsche H, Blumenschein G. Ploidy, proliferative activity and estrogen receptor content in human breast cancer. Cytometry. 1982 Jul; 3(1):36-41. PMID: 7117052.
      View in: PubMed
    171. Kavanagh JJ, Yap HY, Blumenschein GR, Stewart D, Bodey GP. Phase II trail of PCNU in refractory advanced breast cancer. Am J Clin Oncol. 1982 Jun; 5(3):249-51. PMID: 7081144.
      View in: PubMed
    172. Buzdar AU, Legha SS, Blumenschein GR, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Fraschini G, Bodey GP. Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer. 1982 May 01; 49(9):1767-70. PMID: 7042074.
      View in: PubMed
    173. Legha SS, Benjamin RS, Mackay B, Yap HY, Wallace S, Ewer M, Blumenschein GR, Freireich EJ. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer. 1982 May 01; 49(9):1762-6. PMID: 7074581.
      View in: PubMed
    174. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb; 96(2):133-9. PMID: 7059060.
      View in: PubMed
    175. Zander AR, Spitzer G, Legha S, Dicke DA, Verma DS, Johnston DA, Vellekoop L, Beran M, Schell F, Minnhaar G, Blumenschein GR, Bodey GP. High-dose AMSA and bone marrow rescue in patients with solid tumors. Cancer Treat Rep. 1982 Feb; 66(2):385-6. PMID: 7034935.
      View in: PubMed
    176. Ross MB, Buzdar AU, Blumenschein GR. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer. 1982 Feb 01; 49(3):413-7. PMID: 6174195.
      View in: PubMed
    177. Legha SS, Blumenschein GR. Systemic therapy of metastatic breast cancer: a review of the current trends. Oncology. 1982; 39(3):140-5. PMID: 7078937.
      View in: PubMed
    178. Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat. 1982; 2(2):163-9. PMID: 6897369.
      View in: PubMed
    179. Yap HY, Blumenschein GR, Schell FC, Buzdar AU, Valdivieso M, Bodey GP. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med. 1981 Dec; 95(6):694-7. PMID: 7305147.
      View in: PubMed
    180. Yap HY, Blumenschein GR, Bodey GP, Hortobagyi GN, Buzdar AU, DiStefano A. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):775-9. PMID: 7273012.
      View in: PubMed
    181. Rodriguez-Kraul R, Hortobagyi GN, Buzdar AU, Blumenschein GR. Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer. 1981 Jul 15; 48(2):227-32. PMID: 7237395.
      View in: PubMed
    182. Buzdar AU, Legha SS, Hortobagyi GN, Yap HY, Wiseman CL, Distefano A, Schell FC, Barnes BC, Campos LT, Blumenschein GR. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer. 1981 Jun 15; 47(12):2798-802. PMID: 7260870.
      View in: PubMed
    183. Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer. 1981 Jun 15; 47(12):2803-6. PMID: 7260871.
      View in: PubMed
    184. Buzdar AU, Montague ED, Barker JL, Hortobagyi GN, Blumenschein GR. Management of inflammatory carcinoma of breast with combined modality approach - an update. Cancer. 1981 Jun 01; 47(11):2537-42. PMID: 6790155.
      View in: PubMed
    185. Richman SP, Hersh EM, Gutterman JU, Hortobagyi GN, Blumenschein GR, Rios A, Ribi E. Administration of BCG cell wall skeleton into malignant effusions: toxic and therapeutic effects. Cancer Treat Rep. 1981 May-Jun; 65(5-6):383-7. PMID: 7237463.
      View in: PubMed
    186. Yap HY, Blumenschein GR, Schell F, Bodey GP. Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer. Cancer Treat Rep. 1981 May-Jun; 65(5-6):465-7. PMID: 7237467.
      View in: PubMed
    187. Hortobagyi GN, Smith TL, Swenerton KD, Legha SS, Buzdar AU, Blumenschein GR, Gutterman JU, Hersh EM. Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. Cancer. 1981 Mar 15; 47(6):1369-76. PMID: 7226061.
      View in: PubMed
    188. Ho DH, Yap HY, Brown N, Benjamin RS, Friereich EJ, Blumenschein GR, Bodey GP. Clinical pharmacology of intramuscularly administered L-asparaginase. J Clin Pharmacol. 1981 Feb-Mar; 21(2):72-8. PMID: 7229120.
      View in: PubMed
    189. Hortobagyi GN, Blumenschein GR, Buzdar AU, Yap HY, Schell FC, Barnes BC, Burgess MA. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. J Surg Oncol. 1981; 18(2):163-72. PMID: 7300363.
      View in: PubMed
    190. DiStefano A, Yap HY, Blumenschein GR. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP). Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):33-8. PMID: 7013977.
      View in: PubMed
    191. Wiseman CL, Tiber C, Blumenschein GR. Treatment of herniating subdural hematoma. JAMA. 1980 Dec 19; 244(24):2728-9. PMID: 7441857.
      View in: PubMed
    192. Yap BS, Yap HY, Fritsche HA, Blumenschein G, Bodey GP. CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer. JAMA. 1980 Oct 03; 244(14):1601-3. PMID: 7420663.
      View in: PubMed
    193. Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980 Sep; 93(3):399-406. PMID: 6159812.
      View in: PubMed
    194. Legha SS, Buzdar AU, Smith TL, Swenerton KD, Hortobagyi GN, Blumenschein GR. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer. 1980 Aug 01; 46(3):438-45. PMID: 7397619.
      View in: PubMed
    195. Hagemeister FB, Buzdar AU, Luna MA, Blumenschein GR. Causes of death in breast cancer: a clinicopathologic study. Cancer. 1980 Jul 01; 46(1):162-7. PMID: 7388758.
      View in: PubMed
    196. Wiseman C, Cailleau R, Olivé M, Blumenschein GR, Bowen JM. Autologous and homologous immunofluorescent antibody to established breast cancer cell lines. In Vitro. 1980 Jul; 16(7):629-33. PMID: 6997186.
      View in: PubMed
    197. Hug V, Hortobagyi GN, Buzdar AU, Blumenschein GR, Grose W, Burgess MA, Bodey GP. A phase II study of peptichemio in advanced breast cancer. Cancer. 1980 May 15; 45(10):2524-8. PMID: 7378988.
      View in: PubMed
    198. Yap HY, Tashima CK, Blumenschein GR, Hortobagyi GN, Eckles N. Chemotherapy for advanced male breast cancer. JAMA. 1980 May 02; 243(17):1739-41. PMID: 7365938.
      View in: PubMed
    199. DiStefano A, Tashima CK, Fritsche HA, Geitner A, Cailleau R, Blumenschein GR. Carcinoembryonic antigen levels in malignant pleural fluids obtained from patients with mammary cancer. Am J Clin Pathol. 1980 Mar; 73(3):386-9. PMID: 7361717.
      View in: PubMed
    200. Wiseman CL, Bowen JM, Davis JW, Hersh EM, Brown BW, Blumenschein GR. Human lymphocyte blastogenesis responses to mouse mammary tumor virus. J Natl Cancer Inst. 1980 Mar; 64(3):425-30. PMID: 6243719.
      View in: PubMed
    201. Blumenschein GR, Hortobagyi GN, Richman SP, Gutterman JU, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Hersh EM. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. Cancer. 1980 Feb 15; 45(4):742-9. PMID: 6986970.
      View in: PubMed
    202. Krutchik AN, Buzdar AU, Akhtar M, Blumenschein GR. Immune-complex glomerulonephritis secondary to nonspecific immunotherapy. Cancer. 1980 Feb; 45(3):495-7. PMID: 6444365.
      View in: PubMed
    203. Yap HY, Blumenschein GR, Keating MJ, Hortobagyi GN, Tashima CK, Loo TL. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep. 1980 Feb-Mar; 64(2-3):279-83. PMID: 7407762.
      View in: PubMed
    204. Buzdar AU, Legha SS, Luna MA, Tashima CK, Hortobagyi GN, Blumenschein GR. Pulmonary toxicity of mitomycin. Cancer. 1980 Jan 15; 45(2):236-44. PMID: 7351010.
      View in: PubMed
    205. Hortobagyi GN, Yap HY, Wiseman CL, Blumenschein GR, Buzdar AU, Legha SS, Gutterman JU, Hersh EM, Bodey GP. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. Cancer Treat Rep. 1980 Jan; 64(1):157-9. PMID: 6991103.
      View in: PubMed
    206. Benjamin RS, Hortobagyi GN, Swenerton KD, Blumenschein GR, Bodey GP. Strategy for evaluation of a new antitumor agent in the treatment of breast cancer. Recent Results Cancer Res. 1980; 70:153-7. PMID: 7355246.
      View in: PubMed
    207. Legha SS, Buzdar AU, Smith TL, Hortobagyi GN, Swenerton KD, Blumenschein GR, Gehan EA, Bodey GP, Freireich EJ. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med. 1979 Dec; 91(6):847-52. PMID: 517883.
      View in: PubMed
    208. Yap HY, Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Krutchik AN, Benjamin RS, Gutterman JU, Bodey GP. Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. J Surg Oncol. 1979 Dec; 12(4):333-41. PMID: 392197.
      View in: PubMed
    209. Legha SS, Blumenschein GR, Buzdar AU, Hortobagyi GN, Bodey GP. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1961-4. PMID: 526929.
      View in: PubMed
    210. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Nov; 44(5):1955-62. PMID: 387212.
      View in: PubMed
    211. Legha SS, Buzdar AU, Hortobagyi GN, DiStefano A, Wiseman CL, Yap HY, Blumenschein GR, Bodey GP. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2053-6. PMID: 118805.
      View in: PubMed
    212. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer. 1979 Nov; 44(5):1913-8. PMID: 498057.
      View in: PubMed
    213. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, Campos LT, Wheeler WL, Hersh EM, Freireich EJ, Gehan EA. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. JAMA. 1979 Oct 05; 242(14):1509-13. PMID: 470088.
      View in: PubMed
    214. Yap HY, Tashima CK, Blumenschein GR, Eckles N. Diabetes insipidus and breast cancer. Arch Intern Med. 1979 Sep; 139(9):1009-11. PMID: 475518.
      View in: PubMed
    215. Yap HY, Tashima CK, Blumenschein GR, Eckles NE. Male breast cancer: a natural history study. Cancer. 1979 Aug; 44(2):748-54. PMID: 476581.
      View in: PubMed
    216. Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP. Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer. Cancer. 1979 Aug; 44(2):398-405. PMID: 383255.
      View in: PubMed
    217. Legha SS, Buzdar AU, Hortobagyi GN, Wiseman C, Benjamin RS, Blumenschein GR. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA. 1979 Jul 06; 242(1):49-52. PMID: 448865.
      View in: PubMed
    218. Yap HY, Blumenschein GR, Tashima CK, Hortobagyi GN, Buzdar AU, Wiseman CL. Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. Cancer. 1979 Jul; 44(1):32-4. PMID: 222433.
      View in: PubMed
    219. Buzdar AU, Legha SS, Hortobagyi GN, Blumenschein GR. Drug-associated cardiotoxicity. JAMA. 1979 May 04; 241(18):1893. PMID: 430767.
      View in: PubMed
    220. Yap HY, Blumenschein GR, Yap BS, Hortobagyi GN, Tashima CK, Wang AY, Benjamin RS, Bodey GP. High-dose methotrexate for advanced breast cancer. Cancer Treat Rep. 1979 May; 63(5):757-61. PMID: 313246.
      View in: PubMed
    221. Yap HY, Murphy WK, DiStefano A, Blumenschein GR, Bodey GP. Phase II study of anguidine in advanced breast cancer. Cancer Treat Rep. 1979 May; 63(5):789-91. PMID: 455316.
      View in: PubMed
    222. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, Gutterman JU, Blumenschein GR. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979 May; 39(5):1552-62. PMID: 427797.
      View in: PubMed
    223. Hortobagyi GN, DiStefano A, Legha SS, Buzdar AU, Blumenschein GR. Hormonal therapy with tamoxifen in male breast cancer. Cancer Treat Rep. 1979 Apr; 63(4):539-41. PMID: 221118.
      View in: PubMed
    224. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Apr; 43(4):1225-33. PMID: 445325.
      View in: PubMed
    225. Hortobagyi GN, Gutterman JU, Blumenschein GR, Yap HY, Buzdar AU, Tashima CK, Burgess MA, Hersh EM. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. Cancer. 1979 Mar; 43(3):1112-22. PMID: 427716.
      View in: PubMed
    226. Ali MK, Soto A, Maroongroge D, Bekheit-Saad S, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Wiseman CL, Shullenberger CC. Electrocardiographic changes after adriamycin chemotherapy. Cancer. 1979 Feb; 43(2):465-71. PMID: 421174.
      View in: PubMed
    227. Krutchik AN, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Gutterman JU, Yap HY, Hersh EM. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. J Surg Oncol. 1979; 11(4):325-32. PMID: 109703.
      View in: PubMed
    228. Legha SS, Benjamin RS, Buzdar AU, Hortobagyi GN, Blumenschein GR. Rubidazone in metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):135-6. PMID: 369685.
      View in: PubMed
    229. Buzdar AU, Legha SS, Tashima CK, Yap HY, Hortobagyi GN, Hersh EM, Blumenschein GR, Bodey GP. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):115-20. PMID: 369682.
      View in: PubMed
    230. Buzdar AU, Blumenschein GR, Smith TL, Tashima CK, Hortobagyi GN, Yap HY, Gutterman JU, Hersh EM, Gehan EA. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol. 1979; 12(1):27-40. PMID: 480951.
      View in: PubMed
    231. Yap HY, Benjamin RS, Blumenschein GR, Hortobagyi GN, Tashima CK, Buzdar AU, Bodey GP. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):77-83. PMID: 369695.
      View in: PubMed
    232. Krutchik AN, Buzdar AU, Blumenschein GR, Lukeman JM. Spontaneous regression of breast carcinoma. Arch Intern Med. 1978 Nov; 138(11):1734-5. PMID: 718333.
      View in: PubMed
    233. Hortobagyi GN, Yap HY, Blumenschein GR, Gutterman JU, Buzdar AU, Tashima CK, Hersh EM. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin. Cancer Treat Rep. 1978 Nov; 62(11):1685-92. PMID: 728894.
      View in: PubMed
    234. Aldinger KA, Schultz PN, Blumenschein GR, Samaan NA. Thyroid-stimulating hormone and prolactin levels in breast cancer. Arch Intern Med. 1978 Nov; 138(11):1638-41. PMID: 102267.
      View in: PubMed
    235. Hortobagyi GN, Richman SP, Dandridge K, Gutterman JU, Blumenschein GR, Hersh EM. Immunotherapy with BCG administered by scarification: standardization of reactions and management of side effects. Cancer. 1978 Nov; 42(5):2293-303. PMID: 363257.
      View in: PubMed
    236. Krutchik AN, Buzdar AU, Blumenschein GR, Sinkovics JG. Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. Cancer Treat Rep. 1978 Oct; 62(10):1565-7. PMID: 709557.
      View in: PubMed
    237. Krutchik AN, Tashima CK, Buzdar AU, Blumenschein GR. Endobronchial metastases in breast carcinoma. West J Med. 1978 Sep; 129(3):177-80. PMID: 706354.
      View in: PubMed
    238. Krutchik AN, Buzdar A, Tashima CK, Blumenschein GR. Endobronchial metastasis from cancer of the breast. Chest. 1978 Sep; 74(3):319-20. PMID: 688798.
      View in: PubMed
    239. Krutchik AN, Tashima CK, Buzdar AU, Blumenschein GR. Longitudinal nail banding associated with breast carcinoma unrelated to chemotherapy. Arch Intern Med. 1978 Aug; 138(8):1302-3. PMID: 677992.
      View in: PubMed
    240. Buzdar AU, Legha SS, Tashima CK, Hortobagyi GN, Yap HY, Krutchik AN, Luna MA, Blumenschein GR. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep. 1978 Jul; 62(7):1005-8. PMID: 688243.
      View in: PubMed
    241. Yap HY, Yap BS, Tashima CK, DiStefano A, Blumenschein GR. Meningeal carcinomatosis in breast cancer. Cancer. 1978 Jul; 42(1):283-6. PMID: 667799.
      View in: PubMed
    242. Samaan NA, deAsis DN, Buzdar AU, Blumenschein GR. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer. 1978 Jun; 41(6):2084-7. PMID: 418867.
      View in: PubMed
    243. Krutchik AN, Blumenschein GR, Tashima CK, Buzdar AU. Cerebromedullospinal disconnection after intraventricular methotrexate. South Med J. 1978 Apr; 71(4):476-7. PMID: 635633.
      View in: PubMed
    244. Waterfield WC, Tashima CK, Hortobagyi GN, Blumenschein GR, Buzdar AU, Burgess MA. Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. Cancer. 1978 Apr; 41(4):1235-9. PMID: 638989.
      View in: PubMed
    245. Tashima CK, Samaan NA, Blumenschein GR, Hickey RC. Etiologic factors of hypercalcemia in breast cancer. Tex Med. 1978 Mar; 74(3):52-5. PMID: 635813.
      View in: PubMed
    246. Yap HY, Salem P, Hortobagyi GN, Bodey GP, Buzdar AU, Tashima CK, Blumenschein GR. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep. 1978 Mar; 62(3):405-8. PMID: 348308.
      View in: PubMed
    247. Buzdar AU, Gutterman JU, Blumenschein GR, Hortobagyi GN, Tashima CK, Smith TL, Hersh EM, Freireich EJ, Gehan EA. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer. 1978 Mar; 41(3):1064-75. PMID: 638948.
      View in: PubMed
    248. Buzdar AU, Tashima CK, Blumenschein GR, Hortobagyi GN, Yap HY, Krutchik AN, Bodey GP, Livingston RB. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1978 Feb; 41(2):392-5. PMID: 630529.
      View in: PubMed
    249. Buzdar AV, Gutterman JU, Blumenschein GR, Tashima CK, Hortobágyi GN, Yap HY, Hersh EM, Gehan EA. Adjuvant therapy of stage II, III breast cancer. Recent Results Cancer Res. 1978; 68:123-8. PMID: 379930.
      View in: PubMed
    250. Legha SS, Hortobagyi G, Blumenschein GR. Therapy of advanced breast cancer. N Engl J Med. 1977 Dec 08; 297(23):1291-2. PMID: 917079.
      View in: PubMed
    251. Hortobagyi GN, Gutterman JU, Blumenschein GR, Buzdar A, Burgess MA, Richman SP, Tashima CK, Schwarz M, Hersh EM. Chemo immunotherapy of advanced breast cancer with BCG. Recent Results Cancer Res. 1977; (62):143-50. PMID: 601328.
      View in: PubMed
    252. Gutterman JU, Cardenas JO, Blumenschein GR, Hortobagyi G, Burgess MA, Livingston RB, Mavligit GM, Freireich EJ, Gottlieb JA, Hersh EM. Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. Br Med J. 1976 Nov 20; 2(6046):1222-5. PMID: 791447.
      View in: PubMed
    253. Rodriguez V, Gottlieb J, Burgess MA, Livingston R, Wheeler W, Spitzer G, Bodey GP, Blumenschein GR, Freireich EJ. Phase I studies with Baker's Antifol (BAF) (NSC 139105). Cancer. 1976 Aug; 38(2):690-4. PMID: 974989.
      View in: PubMed
    254. Benjamin RS, Hall SW, Burgess MA, Wheeler WL, Murphy WK, Blumenschein GR, Gottlieb JA. A pharmacokinetically based phase I-II study of single-dose actinomycin D (NSC-3053). Cancer Treat Rep. 1976 Mar; 60(3):289-91. PMID: 1260785.
      View in: PubMed
    255. Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SE, Bodey GP, Rodriguez V, Blumenschein GR, Saiki JH, Coltman C, Burgess MA, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon TE. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 1976 Feb; 60(2):199-203. PMID: 769974.
      View in: PubMed
    256. Shambaugh GE, Blumenschein GR. Combined effects of phytohemagglutinin and staphylococcal enterotoxin B on deoxyribonucleic acid synthesis during blast transformation in human lymphocytes. Infect Immun. 1974 Feb; 9(2):384-90. PMID: 4361297.
      View in: PubMed
    257. Hickey RC, Blumenschein GR, McHardy G, Hightower NC. Telephone consultation--dial access: a project in cancer education and control. South Med J. 1973 Oct; 66(10):1159-62. PMID: 4745102.
      View in: PubMed
    258. Paterson PY, Semo R, Blumenschein G, Swelstad J. Mucocutaneous candidiasis, anergy and a plasma inhibitor of cellular immunity: reversal after amphotericin B therapy. Clin Exp Immunol. 1971 Nov; 9(5):595-602. PMID: 4947556.
      View in: PubMed
    259. Grant JA, Blumenschein GR, Buckley CE. Familial paraproteinemia. Arch Intern Med. 1971 Sep; 128(3):427-31. PMID: 4106045.
      View in: PubMed
    260. Woods R, Blumenschein GR, Terry WD. A new type of human gamma heavy chain disease protein: immunochemical and physical characteristics. Immunochemistry. 1970 Apr; 7(4):373-81. PMID: 4194087.
      View in: PubMed
    261. Blumenschein GR, Moloney JB. Quantitative dose-response relationships of murine sarcoma virus (Moloney) in BALB/c mice. J Natl Cancer Inst. 1969 Jan; 42(1):123-33. PMID: 5765223.
      View in: PubMed
    262. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Annals of Oncology. 26:894-901.
    263. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. The Lancet Oncology. 17:1672-1682.
    264. Epidermal growth factor receptor P753S mutation in cutaneous squamous cell carcinoma responsive to cetuximab-based therapy. Journal of Clinical Oncology. 34:e34-e37.
    265. Immunotherapy for non-small cell lung cancer. Chinese Journal of Lung Cancer. 16:9-20.
    266. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Frontiers in Oncology. 1.
    267. Role of HGF/MET axis in resistance of lung cancer to contemporary management. Translational Lung Cancer Research. 1:179-193.
    268. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head and Neck. 37:644-649.
    269. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 7:23227-23238.
    BLUMENSCHEIN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description